FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2101474712> ?p ?o ?g. }

• W2101474712 endingPage "305" @default.
• W2101474712 startingPage "298" @default.
• W2101474712 abstract "Abstract Aim: Advanced esophagogastric carcinoma has a poor prognosis. Palliative chemotherapy provides a survival advantage and improved quality of life. Epirubicin, cisplatin and continuous infusional 5‐fluorouracil (5‐FU) (ECF) is a well‐established chemotherapy regimen but a continuous chemotherapy infusion is not always feasible or acceptable. Methods: We conducted a phase I and II trial of a modified version of ECF, utilizing 5‐FU as a 24‐h infusion on day 1 and day 8 of a 21‐day cycle, administered with sodium folinate as a modulator of 5‐FU (ECSF). In the phase I study the dose of 5‐FU was increased in successive cohorts from 1250 mg/m 2 , 1500 mg/m 2 , and 1750 mg/m 2 to 2000 mg/m 2 per 24 h. Results: Dose limiting toxicity of febrile neutropenia was encountered at 2000 mg/m. The recommended dose for 5‐FU was 1750 mg/m 2 . Overall 29 patients were treated with ECSF of whom 27 were evaluable for toxicity. The response rate was 45% on an intention‐to‐treat analysis with a complete response rate of 3%. The median response rate was 4.1 months and the median survival was 10.7 months. A total of 23 patients (72%) obtained clinical benefit with improvement in dysphagia or weight gain. central venous catheter (CVC) complications were observed in 12 (41%) patients. Conclusion: ECSF was associated with a response rate and survival similar to that reported with standard ECF. ECSF may provide an alternative regimen to standard ECF when a continuous ambulatory infusion pump is not feasible or not preferred by the patient. CVC complications are a limitation." @default.
• W2101474712 created "2016-06-24" @default.
• W2101474712 creator A5012142507 @default.
• W2101474712 creator A5040618086 @default.
• W2101474712 creator A5052620856 @default.
• W2101474712 creator A5057369891 @default.
• W2101474712 creator A5060575280 @default.
• W2101474712 creator A5064106888 @default.
• W2101474712 creator A5068720728 @default.
• W2101474712 creator A5076548846 @default.
• W2101474712 creator A5082293028 @default.
• W2101474712 date "2010-11-03" @default.
• W2101474712 modified "2023-10-17" @default.
• W2101474712 title "A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas" @default.
• W2101474712 cites W1625189041 @default.
• W2101474712 cites W1843791750 @default.
• W2101474712 cites W1849132397 @default.
• W2101474712 cites W1863898801 @default.
• W2101474712 cites W1897637667 @default.
• W2101474712 cites W1930945683 @default.
• W2101474712 cites W1940613095 @default.
• W2101474712 cites W1976651872 @default.
• W2101474712 cites W1992408996 @default.
• W2101474712 cites W2022648896 @default.
• W2101474712 cites W2050057988 @default.
• W2101474712 cites W2059072983 @default.
• W2101474712 cites W2061112867 @default.
• W2101474712 cites W2095256813 @default.
• W2101474712 cites W2111513457 @default.
• W2101474712 cites W2127773543 @default.
• W2101474712 cites W2128328462 @default.
• W2101474712 cites W2129569499 @default.
• W2101474712 cites W2130522735 @default.
• W2101474712 cites W2131212105 @default.
• W2101474712 cites W2143863553 @default.
• W2101474712 cites W2167112387 @default.
• W2101474712 cites W2246437066 @default.
• W2101474712 cites W2262941006 @default.
• W2101474712 cites W2269468903 @default.
• W2101474712 cites W2338880854 @default.
• W2101474712 cites W2599982658 @default.
• W2101474712 cites W2602544133 @default.
• W2101474712 doi "https://doi.org/10.1111/j.1743-7563.2010.01340.x" @default.
• W2101474712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21114780" @default.
• W2101474712 hasPublicationYear "2010" @default.
• W2101474712 type Work @default.
• W2101474712 sameAs 2101474712 @default.
• W2101474712 citedByCount "5" @default.
• W2101474712 countsByYear W21014747122012 @default.
• W2101474712 countsByYear W21014747122013 @default.
• W2101474712 countsByYear W21014747122017 @default.
• W2101474712 countsByYear W21014747122019 @default.
• W2101474712 crossrefType "journal-article" @default.
• W2101474712 hasAuthorship W2101474712A5012142507 @default.
• W2101474712 hasAuthorship W2101474712A5040618086 @default.
• W2101474712 hasAuthorship W2101474712A5052620856 @default.
• W2101474712 hasAuthorship W2101474712A5057369891 @default.
• W2101474712 hasAuthorship W2101474712A5060575280 @default.
• W2101474712 hasAuthorship W2101474712A5064106888 @default.
• W2101474712 hasAuthorship W2101474712A5068720728 @default.
• W2101474712 hasAuthorship W2101474712A5076548846 @default.
• W2101474712 hasAuthorship W2101474712A5082293028 @default.
• W2101474712 hasConcept C126322002 @default.
• W2101474712 hasConcept C141071460 @default.
• W2101474712 hasConcept C2776283816 @default.
• W2101474712 hasConcept C2776694085 @default.
• W2101474712 hasConcept C2776755627 @default.
• W2101474712 hasConcept C2777063308 @default.
• W2101474712 hasConcept C2778239845 @default.
• W2101474712 hasConcept C2778496288 @default.
• W2101474712 hasConcept C2778850193 @default.
• W2101474712 hasConcept C2780456651 @default.
• W2101474712 hasConcept C2780835546 @default.
• W2101474712 hasConcept C2781413609 @default.
• W2101474712 hasConcept C29730261 @default.
• W2101474712 hasConcept C71924100 @default.
• W2101474712 hasConcept C90924648 @default.
• W2101474712 hasConceptScore W2101474712C126322002 @default.
• W2101474712 hasConceptScore W2101474712C141071460 @default.
• W2101474712 hasConceptScore W2101474712C2776283816 @default.
• W2101474712 hasConceptScore W2101474712C2776694085 @default.
• W2101474712 hasConceptScore W2101474712C2776755627 @default.
• W2101474712 hasConceptScore W2101474712C2777063308 @default.
• W2101474712 hasConceptScore W2101474712C2778239845 @default.
• W2101474712 hasConceptScore W2101474712C2778496288 @default.
• W2101474712 hasConceptScore W2101474712C2778850193 @default.
• W2101474712 hasConceptScore W2101474712C2780456651 @default.
• W2101474712 hasConceptScore W2101474712C2780835546 @default.
• W2101474712 hasConceptScore W2101474712C2781413609 @default.
• W2101474712 hasConceptScore W2101474712C29730261 @default.
• W2101474712 hasConceptScore W2101474712C71924100 @default.
• W2101474712 hasConceptScore W2101474712C90924648 @default.
• W2101474712 hasIssue "4" @default.
• W2101474712 hasLocation W21014747121 @default.
• W2101474712 hasLocation W21014747122 @default.
• W2101474712 hasOpenAccess W2101474712 @default.
• W2101474712 hasPrimaryLocation W21014747121 @default.
• W2101474712 hasRelatedWork W139966500 @default.

• next